S Pilemann-Lyberg1, M Lindhardt2, Frederik Persson3, S Andersen4, P Rossing5. 1. Department of Endocrinology, MEA, NBG, Institute for Clinical Medicine, Aarhus University Hospital, Denmark; Steno Diabetes Center Copenhagen, Gentofte, Denmark. Electronic address: sascha.maria.pilemann-lyberg@regionh.dk. 2. Steno Diabetes Center Copenhagen, Gentofte, Denmark. Electronic address: morten.kofod.lindhardt@regionh.dk. 3. Steno Diabetes Center Copenhagen, Gentofte, Denmark. Electronic address: frederik.ivar.persson@regionh.dk. 4. Nordsjaellands Hospital, Hilleroed, Denmark. Electronic address: steen.andersen.02@regionh.dk. 5. Steno Diabetes Center Copenhagen, Gentofte, Denmark; Institute of Clinical Medicine, University of Copenhagen, Denmark; Aarhus University, Denmark. Electronic address: peter.rossing@regionh.dk.
Abstract
AIMS: Uric acid (UA) is a risk factor for CKD. We evaluated UA in relation to change in GFR in patients with type 1 diabetes. METHODS: Post hoc analysis of a trial of losartan in diabetic nephropathy, mean follow-up 3 years (IQR 1.5-3.5). UA was measured at baseline. Primary end-point was change in measured GFR. UA was tested in a linear regression model adjusted for known progression factors (gender, HbA1c, systolic blood pressure, cholesterol, baseline GFR and baseline urinary albumin excretion rate (UAER)). RESULTS: Baseline UA was 0.339 mmol/l (SD ±0.107), GFR 87 ml/min/1.73 m2 (±23), geometric mean UAER 1023 mg/24 h (IQR, 631 - 1995). Mean rate of decline in GFR was 4.6 (3.7) ml/min/year. In the upper quartile of baseline UA the mean decline in GFR from baseline to the end of the study was 6.2 (4.9) ml/min/1.73 m2 and 4.1 (3.1) ml/min/1.73 m2 in the three lower quartiles of UA, (p = 0.088). In a linear model including baseline covariates (UAER, GFR, total cholesterol, HDL cholesterol) UA was associated with decline in GFR (r2 = 0.45, p < 0.001). CONCLUSION: Uric acid was weakly associated with decline in GFR in type 1 diabetic patients with overt nephropathy.
AIMS: Uric acid (UA) is a risk factor for CKD. We evaluated UA in relation to change in GFR in patients with type 1 diabetes. METHODS: Post hoc analysis of a trial of losartan in diabetic nephropathy, mean follow-up 3 years (IQR 1.5-3.5). UA was measured at baseline. Primary end-point was change in measured GFR. UA was tested in a linear regression model adjusted for known progression factors (gender, HbA1c, systolic blood pressure, cholesterol, baseline GFR and baseline urinary albumin excretion rate (UAER)). RESULTS: Baseline UA was 0.339 mmol/l (SD ±0.107), GFR 87 ml/min/1.73 m2 (±23), geometric mean UAER 1023 mg/24 h (IQR, 631 - 1995). Mean rate of decline in GFR was 4.6 (3.7) ml/min/year. In the upper quartile of baseline UA the mean decline in GFR from baseline to the end of the study was 6.2 (4.9) ml/min/1.73 m2 and 4.1 (3.1) ml/min/1.73 m2 in the three lower quartiles of UA, (p = 0.088). In a linear model including baseline covariates (UAER, GFR, total cholesterol, HDL cholesterol) UA was associated with decline in GFR (r2 = 0.45, p < 0.001). CONCLUSION:Uric acid was weakly associated with decline in GFR in type 1 diabeticpatients with overt nephropathy.
Authors: Alicia J Jenkins; Barbara H Braffett; Arpita Basu; Ionut Bebu; Samuel Dagogo-Jack; Trevor J Orchard; Amisha Wallia; Maria F Lopes-Virella; W Timothy Garvey; John M Lachin; Timothy J Lyons Journal: Sci Rep Date: 2021-07-09 Impact factor: 4.379